Profile: DiaMedica Therapeutics Inc (DMAC.OQ)

DMAC.OQ on NASDAQ Stock Exchange Capital Market

10:21pm IST
Change (% chg)

$0.01 (+0.35%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

DiaMedica Therapeutics Inc is a Canada-based clinical-stage biopharmaceutical company, which focuses on recombinant proteins and monoclonal antibodies. The Company focuses on the discovery and development of treatments for stroke and other vascular diseases. It operates through segment, which is discovery and development of recombinant proteins and monoclonal antibody technology applications to treat large unmet diseases, including acute vascular disease of the brain, kidneys and heart. Its product, DM199, is a recombinant human tissue kallikrein-1 protein engineered to duplicate the actions of the naturally occurring human kallikrein-1 protein produced in the pancreas, kidneys and salivary glands of humans as a response to oxidative stress challenges. Its drug, Recombinant tissue plasminogen activator, is intended for the treatment of acute ischemic stroke (AIS). DM199 has also completed a Phase I/II clinical trials in Type 2 diabetic patients.

Company Address

DiaMedica Therapeutics Inc

2 Carlson Pkwy N Ste 260
MINNEAPOLIS   MN   55447-4477
P: +1763.4965454
F: +1763.7104456

Company Web Links